Biotechnology

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?

A two-year delay for Carbios' biorecycling plant in China isn't a failure, but a harsh lesson in scaling innovation. Here's what it means for the future.

NexTel Medical acquires two telehealth firms for an instant $135K in monthly revenue, aiming to launch its Maxasome™ exosome therapies to 1,850 clinics.

A small startup just raised $4M to solve the biggest problem in tech: making AR glasses affordable. Their secret isn't a new gadget, but a materials science breakthrough.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

As its CEO heads to a top investor conference, Zealand Pharma leverages AI and novel peptides to challenge giants in the multi-billion-dollar obesity market.

A new study reveals an 'early warning system' in infant guts, offering a window to combat the atopic march before allergies take hold. Is this the future?

As psychedelics go mainstream, a new initiative asks a hard question: what about those most harmed by their prohibition? MAPS' latest project is a radical rethink.

Cell therapies promise miracles, but a decades-old test for cell health is flawed. A new global standard aims to bring much-needed precision and safety.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Montara Therapeutics' new MJFF grant isn't just about Parkinson's. It's a bet on a 'BrainOnly' platform that could unlock a new era for CNS therapies.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.